New Delhi: The national drug pricing regulator, National Pharmaceutical Pricing Authority, has capped price of additional 36 drugs, including those used to treat infections and diabetes. The move will make essential medicines more affordable.
The new list under the drug price control order (DPCO) covers major anti-infectives, followed by gastro drugs and vaccines. These medicines join the 348 essential list of medicines on which the government had announced price caps last year.
The major impact will be on the molecule, Ciprofloxacin 500 and 250 mg, a popular antibiotic manufactured by companies like Ranbaxy and Cipla. Other medicines which are part of the list include Rifampicin, Cloxacillin, Enalapril, Cefotaxime, Didanosine and the BCG vaccine.
Companies like Cipla, Ranbaxy, Cadila Healthcare, Alkem and Pfizer are among those that will be affected by the latest decision, research firm AIOCD AWACS said.
